PMID- 34292177
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20230208
IS  - 1473-6322 (Electronic)
IS  - 1473-6322 (Linking)
VI  - 21
IP  - 5
DP  - 2021 Oct 1
TI  - Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic 
      review.
PG  - 426-434
LID - 10.1097/ACI.0000000000000768 [doi]
AB  - PURPOSE OF REVIEW: Mast cell activation syndrome (MCAS) and anaphylaxis are the 
      result of a spontaneous or triggered pathological degranulation of mast cells 
      (MCs) and might have as substrate normal or pathological MCs (increased burden, 
      aberrant MCs or both). RECENT FINDINGS: This review summarizes the most recent 
      evidence on immunoglobulin E (IgE)-mediated and non IgE-mediated mechanisms 
      underlying MC activation and degranulation and highlights the importance of 
      standardized diagnostic criteria for MCAS. Application of these criteria implies 
      that in most cases the clinical presentation of MCAS meets the diagnostic 
      criteria for anaphylaxis. SUMMARY: Integrating clinical parameters and diagnostic 
      test recognition and underlying clonal MC disease are of utmost importance for a 
      patient-tailored approach. Hereditary alpha-tryptasemia can be encountered in 
      context of anaphylaxis, MCAS and primary MC disorders.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Sabato, Vito
AU  - Sabato V
AD  - University of Antwerp, Faculty of Medicine and Health Sciences, Department of 
      Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence.
AD  - AZ Jan Palfijn Gent, Department of Immunology and Allergology, Ghent, Belgium.
FAU - Michel, Moise
AU  - Michel M
AD  - Laboratoire d'Immunologie, CHU de Nimes, Nimes.
AD  - Aix-Marseille Univ, IRD, APHM, MEPHI.
AD  - IHU Mediterranee Infection, Marseille.
FAU - Blank, Ulrich
AU  - Blank U
AD  - Universite de Paris, Centre de Recherche sur l'Inflammation, INSERM UMR1149, CNRS 
      ERL8252, Faculte de Medecine site Bichat, Paris, France; Laboratoire d'Excellence 
      Inflamex, Paris, France.
FAU - Ebo, Didier G
AU  - Ebo DG
AD  - University of Antwerp, Faculty of Medicine and Health Sciences, Department of 
      Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence.
AD  - AZ Jan Palfijn Gent, Department of Immunology and Allergology, Ghent, Belgium.
FAU - Vitte, Joana
AU  - Vitte J
AD  - Aix-Marseille Univ, IRD, APHM, MEPHI.
AD  - IHU Mediterranee Infection, Marseille.
AD  - IDESP, INSERM UMR UA 11, Montpellier, France.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
PL  - United States
TA  - Curr Opin Allergy Clin Immunol
JT  - Current opinion in allergy and clinical immunology
JID - 100936359
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - *Anaphylaxis/diagnosis
MH  - Humans
MH  - Immunoglobulin E
MH  - Mast Cell Activation Syndrome/*diagnosis
MH  - Mast Cells
MH  - Phenotype
EDAT- 2021/07/23 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/07/22 12:22
PHST- 2021/07/23 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/07/22 12:22 [entrez]
AID - 00130832-202110000-00004 [pii]
AID - 10.1097/ACI.0000000000000768 [doi]
PST - ppublish
SO  - Curr Opin Allergy Clin Immunol. 2021 Oct 1;21(5):426-434. doi: 
      10.1097/ACI.0000000000000768.